Literature DB >> 27825693

Use of nitroglycerin by bolus prevents intensive care unit admission in patients with acute hypertensive heart failure.

Suprat Saely Wilson1, Gregory M Kwiatkowski1, Scott R Millis2, John D Purakal2, Arushi P Mahajan2, Phillip D Levy3.   

Abstract

OBJECTIVES: The purpose of this study was to compare health care resource utilization among patients who were given intravenous nitroglycerin for acute heart failure (AHF) in the emergency department (ED) by intermittent bolus, continuous infusion, or a combination of both.
METHODS: We retrospectively identified 395 patients that received nitroglycerin therapy in the ED for the treatment of AHF over a 5-year period. Patients that received intermittent bolus (n=124) were compared with continuous infusion therapy (n=182) and combination therapy of bolus and infusion (n=89). The primary outcomes were the frequency of intensive care unit (ICU) admission and hospital length of stay (LOS).
RESULTS: On unadjusted analysis, rates of ICU admission were significantly lower in the bolus vs infusion and combination groups (48.4% vs 68.7% vs 83%, respectively; P<.0001) and median LOS (interquartile range) was shorter (3.7 [2.5-6.2 days]) compared with infusion (4.7 [2.9-7.1 days]) and combination (5.0 [2.9-6.7 days]) groups; P=.02. On adjusted regression models, the strong association between bolus nitroglycerin and reduced ICU admission rate remained, and hospital LOS was 1.9 days shorter compared with infusion therapy alone. Use of intubation (bolus [8.9%] vs infusion [8.8%] vs combination [16.9%]; P=.096) and bilevel positive airway pressure (bolus [26.6%] vs infusion [20.3%] vs combination [29.2%]; P=.21) were similar as was the incidence of hypotension, myocardial injury, and worsening renal function.
CONCLUSIONS: In ED patients with AHF, intravenous nitroglycerin by intermittent bolus was associated with a lower ICU admission rate and a shorter hospital LOS compared with continuous infusion.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27825693     DOI: 10.1016/j.ajem.2016.10.038

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  7 in total

Review 1.  Diagnosis and Management of Acute Heart Failure in Sub-Saharan Africa.

Authors:  Alice Kidder Bukhman; Vizir Jean Paul Nsengimana; Mindy C Lipsitz; Patricia C Henwood; Endale Tefera; Shada A Rouhani; Damas Dukundane; Gene Y Bukhman
Journal:  Curr Cardiol Rep       Date:  2019-08-31       Impact factor: 2.931

Review 2.  Blood Pressure Reduction in Hypertensive Acute Heart Failure.

Authors:  Nicholas Harrison; Peter Pang; Sean Collins; Phillip Levy
Journal:  Curr Hypertens Rep       Date:  2021-02-20       Impact factor: 5.369

Review 3.  Optimizing Hypertensive Acute Heart Failure Management with Afterload Reduction.

Authors:  Sean Collins; Jennifer Martindale
Journal:  Curr Hypertens Rep       Date:  2018-02-24       Impact factor: 5.369

4.  Adult Patients with Respiratory Distress: Current Evidence-based Recommendations for Prehospital Care.

Authors:  Sammy S Hodroge; Melody Glenn; Amelia Breyre; Bennett Lee; Nick R Aldridge; Karl A Sporer; Kristi L Koenig; Marianne Gausche-Hill; Angelo A Salvucci; Eric M Rudnick; John F Brown; Gregory H Gilbert
Journal:  West J Emerg Med       Date:  2020-06-25

5.  Treating acute hypertensive cardiogenic pulmonary edema with high-dose nitroglycerin.

Authors:  Yi-Ting Hsieh; Tai-Ying Lee; Jui-Shih Kao; Hsin-Lin Hsu; Chee-Fah Chong
Journal:  Turk J Emerg Med       Date:  2018-02-02

6.  Ultra-high dose intravenous nitroglycerin in an ESRD patient with acutely decompensated heart failure.

Authors:  Michael Gyory; Samantha Abdallah; Anthony Lagina; Phillip D Levy; Michael J Twiner
Journal:  J Am Coll Emerg Physicians Open       Date:  2021-03-02

Review 7.  Nitroglycerin Use in the Emergency Department: Current Perspectives.

Authors:  Michael J Twiner; John Hennessy; Rachel Wein; Phillip D Levy
Journal:  Open Access Emerg Med       Date:  2022-07-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.